Inspira Technologies Faces Nasdaq Minimum Bid Price Deficiency, Retains Listing Through Compliance Window

Inspira Technologies Oxy BHN ( (IINN) ) has shared an announcement.

Inspira Technologies OXY B.H.N. Ltd., a commercial-stage MedTech company, develops advanced respiratory support systems and blood monitoring technologies, including the FDA-cleared INSPIRA ART100 and its next-generation INSPIRA ART500 platform. The company is also advancing its HYLA blood sensor technology as it pursues a broader role in the global life-support device market.

On February 12, 2026, Inspira Technologies disclosed that it received a Nasdaq notice on February 9 stating its shares had failed to meet the $1.00 minimum bid price for 30 consecutive business days. The stock remains listed on the Nasdaq Capital Market as the company now has until August 10, 2026, to restore compliance, with the potential for an additional 180-day extension or, failing that, a possible delisting if it cannot meet the exchange’s requirements.

The most recent analyst rating on (IINN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.

The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies OXY B.H.N. Ltd. is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system supports cardiopulmonary bypass in the U.S. and ECMO procedures abroad, while the INSPIRA ART500 and HYLA blood sensor platform aim to expand its footprint in the life-support and MedTech markets.

The company leverages multiple cleared products, a growing intellectual property portfolio, and streamlined operations to strengthen its position as an emerging platform player. By targeting both hospital-based life-support systems and continuous, non-invasive blood monitoring, Inspira is seeking to capture demand in critical care and advanced diagnostics globally.

Average Trading Volume: 570,558

Technical Sentiment Signal: Sell

Current Market Cap: $26.15M

For a thorough assessment of IINN stock, go to TipRanks’ Stock Analysis page.